| NCT ID | NCT03303833 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wageningen University |
| Condition | Lynch Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2006-07-01 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2006-07-01 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The GEOLynch cohort study has been established to investigate the influence of genetic, environmental and other factors on tumour risk in persons with Lynch syndrome.
Eligibility Criteria
Inclusion Criteria: * Persons with a known mutation in a gene that causes Lynch syndrome, i.e. with an inherited monoallelic pathogenic germline mutation in either the MLH1, MSH2, MSH6, PMS2 or EPCAM gene. * Aged between 18 and 80 years at inclusion. Exclusion Criteria: * Additional carrier of another hereditary colon cancer predisposition syndrome (e.g. FAP) * (Chronic) Inflammatory bowel disease * Non-Dutch speaking * Dementia or another mental condition that makes it impossible to fill out questionnaires * Terminally ill persons
Contact & Investigator
Ellen Kampman, PhD
PRINCIPAL INVESTIGATOR
Wageningen University
Frequently Asked Questions
Who can join the NCT03303833 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Lynch Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03303833 currently recruiting?
Yes, NCT03303833 is actively recruiting participants. Contact the research team at franzel.vanduijnhoven@wur.nl for enrollment information.
Where is the NCT03303833 trial being conducted?
This trial is being conducted at Wageningen, Netherlands.
Who is sponsoring the NCT03303833 clinical trial?
NCT03303833 is sponsored by Wageningen University. The principal investigator is Ellen Kampman, PhD at Wageningen University. The trial plans to enroll 1,000 participants.